Theravance Biopharma TBPH
NASDAQ TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) EV to EBIT (2026)

Updated

Theravance Biopharma's (TBPH) EV to EBIT stood at 327.22 in Q1 2026.

Analysis

Theravance Biopharma (TBPH) EV to EBIT (2026) Analysis & Trends

On a TTM basis, Theravance Biopharma's EV to EBIT came in at -402.09 as of Mar 31, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Theravance Biopharma 883.70 Mn -543.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 327.22
API Access

Theravance Biopharma EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=TBPH&period=max&api_key=YOUR_API_KEY